Shattuck Labs registers Phase 2 trial of SL-325 in Crohn's disease
A new placebo-controlled study of SL-325 for moderately to severely active Crohn's disease was listed on ClinicalTrials.gov, not yet recruiting.
Shattuck Labs had one registry update for the week.
- Shattuck Labs registered a Phase 2 study, "RECEPTIVE-CD1" (NCT07753850), testing intravenous SL-325 against placebo in adults with moderately to severely active Crohn's disease. The trial plans to enroll 232 participants across high, mid, and low dose SL-325 arms plus placebo.1 The study's primary outcome is the proportion of participants who achieve endoscopic response at Week 12, defined as a 50% or greater decrease in Simplified Endoscopic Score for Crohn's disease from baseline.1 The record lists the trial as not yet recruiting, with an estimated start of October 2026.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.